• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

综述文章:炎症性肠病患者对其临床管理有何期望?

Review article: what do patients with inflammatory bowel disease want for their clinical management?

作者信息

Westwood N, Travis S P L

机构信息

National Association of Colitis and Crohn's Disease, UK.

出版信息

Aliment Pharmacol Ther. 2008 Mar;27 Suppl 1:1-8. doi: 10.1111/j.1365-2036.2008.03605.x.

DOI:10.1111/j.1365-2036.2008.03605.x
PMID:18307643
Abstract

BACKGROUND

The patient's perceptions of benefits and risks of treatment differ from those of physicians, yet this topic is rarely explored in ulcerative colitis or Crohn's disease.

AIM

To present a patient's perspective on care for their colitis, to consider how patients' views will influence preliminary proposals for standards of care, and to discuss the different priorities of patients and physicians.

METHODS

Description of an individual patient's journey from diagnosis of ulcerative colitis to colectomy, compared with priorities proposed by a patient-based organization (National Association of Colitis and Crohn's disease).

RESULTS

Awareness of colitis in primary care, prompt referral, timely investigation and specialist care if admitted to hospital are shared goals of patients and physicians. Patients are generally prepared to accept higher risks from medical treatment to avoid their undesirable outcomes (especially colectomy) than physicians will on their behalf. There has been little systematic study of this disparity in ulcerative colitis. Under-reporting the symptom burden, tolerance of treatment side effects, substantial lifestyle changes and willingness to explore any treatment options are characteristic coping strategies. Physicians should be alert to coping strategies, with a willingness to seek second opinions.

CONCLUSION

Perceptions of risk and benefit differ between patients and physicians, and recognition of this difference is a starting point for difficult clinical decision-making.

摘要

背景

患者对治疗益处和风险的认知与医生不同,但在溃疡性结肠炎或克罗恩病中,这一话题很少被探讨。

目的

呈现患者对结肠炎护理的观点,思考患者的观点将如何影响护理标准的初步提议,并讨论患者和医生不同的优先事项。

方法

描述一名溃疡性结肠炎患者从诊断到结肠切除术的历程,并与一个以患者为基础的组织(全国结肠炎和克罗恩病协会)提出的优先事项进行比较。

结果

初级保健中对结肠炎的认识、及时转诊、及时检查以及住院时的专科护理是患者和医生的共同目标。与医生相比,患者通常愿意接受更高的医疗风险以避免不良后果(尤其是结肠切除术)。在溃疡性结肠炎中,对这种差异几乎没有进行系统研究。对症状负担报告不足、对治疗副作用的耐受、生活方式的大幅改变以及愿意探索任何治疗方案是典型的应对策略。医生应警惕这些应对策略,并愿意寻求第二种意见。

结论

患者和医生对风险和益处的认知不同,认识到这种差异是艰难临床决策的起点。

相似文献

1
Review article: what do patients with inflammatory bowel disease want for their clinical management?综述文章:炎症性肠病患者对其临床管理有何期望?
Aliment Pharmacol Ther. 2008 Mar;27 Suppl 1:1-8. doi: 10.1111/j.1365-2036.2008.03605.x.
2
Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study.患者对炎症性肠病治疗中共同决策的偏好:一项患者赋权研究的结果。
Digestion. 2010;81(2):113-9. doi: 10.1159/000253862. Epub 2010 Jan 9.
3
Psychosocial correlates of patient-physician discordance in inflammatory bowel disease.炎症性肠病中患者与医生意见不一致的社会心理相关因素。
Am J Gastroenterol. 2002 Sep;97(9):2174-83. doi: 10.1111/j.1572-0241.2002.05969.x.
4
Patient involvement in setting research agendas.患者参与制定研究议程。
Eur J Gastroenterol Hepatol. 2006 Sep;18(9):935-8. doi: 10.1097/01.meg.0000230089.68545.45.
5
C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.C反应蛋白:炎症性肠病中炎症的预测因子和标志物。一项基于人群的前瞻性研究结果
Gut. 2008 Nov;57(11):1518-23. doi: 10.1136/gut.2007.146357. Epub 2008 Jun 19.
6
Review article: patients' fears and unmet needs in inflammatory bowel disease.综述文章:炎症性肠病患者的恐惧与未满足的需求
Aliment Pharmacol Ther. 2004 Oct;20 Suppl 4:54-9. doi: 10.1111/j.1365-2036.2004.02053.x.
7
[Education of patients with inflammatory bowel diseases].
Wien Med Wochenschr. 1999;149(12):352-4.
8
Finnish patients with inflammatory bowel disease have fewer symptoms and are more satisfied with their treatment than patients in the previous European survey.与之前欧洲调查中的患者相比,芬兰炎症性肠病患者的症状更少,对治疗也更满意。
Scand J Gastroenterol. 2008;43(7):821-30. doi: 10.1080/00365520801912011.
9
[Preference of patients with inflammatory bowel disease regarding information and shared decision-making: results from a cross-sectional survey in Germany].[炎症性肠病患者对信息及共同决策的偏好:德国一项横断面调查的结果]
Z Gastroenterol. 2012 Apr;50(4):364-72. doi: 10.1055/s-0031-1281949. Epub 2012 Apr 1.
10
[Physician-patient relations and stress caused by coloscopy in patients with chronic inflammatory bowel disease].[慢性炎症性肠病患者的医患关系及结肠镜检查引起的应激反应]
Schweiz Med Wochenschr Suppl. 1996;79:94S-96S.

引用本文的文献

1
"My UC Story": A Qualitative Descriptive Study Describing the Patient Journey for Ulcerative Colitis.“我的溃疡性结肠炎故事”:一项描述溃疡性结肠炎患者就医历程的质性描述性研究
Innov Pharm. 2023 Nov 20;14(4). doi: 10.24926/iip.v14i4.5697. eCollection 2023.
2
Patient and Caregiver Perspectives on Their Experiences With Crohn's Perianal Fistulas.患者及护理人员对克罗恩病肛周瘘管经历的看法。
Crohns Colitis 360. 2024 Jan 6;6(1):otad081. doi: 10.1093/crocol/otad081. eCollection 2024 Jan.
3
Concordance and Discordance Between Patient-reported Remission, Patient-reported Outcomes, and Physician Global Assessment.
患者报告的缓解、患者报告的结局与医生整体评估的一致性和不一致性。
Inflamm Bowel Dis. 2023 Aug 1;29(8):1255-1262. doi: 10.1093/ibd/izac206.
4
Acceptability of a 'treat to target' approach in inflammatory bowel disease to patients in clinical remission.炎症性肠病“达标治疗”方法对临床缓解期患者的可接受性。
Frontline Gastroenterol. 2020 Jan 24;12(1):30-38. doi: 10.1136/flgastro-2019-101366. eCollection 2021.
5
Adapting to ulcerative colitis to try to live a 'normal' life: a qualitative study of patients' experiences in the Midlands region of England.适应溃疡性结肠炎,努力过“正常”生活:英格兰中部地区患者体验的定性研究。
BMJ Open. 2017 Aug 21;7(8):e017544. doi: 10.1136/bmjopen-2017-017544.
6
Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment.炎症性肠病:有效维持缓解对于控制成本至关重要。
World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):114-119. doi: 10.4292/wjgpt.v8.i2.114.
7
Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.粪便钙卫蛋白监测在无症状炎症性肠病患者中的临床应用:一项系统评价与实用指南
Inflamm Bowel Dis. 2017 Jun;23(6):894-902. doi: 10.1097/MIB.0000000000001082.
8
Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers.预测生物治疗的前瞻性讨论:炎症性肠病患者及其处方医生的开放性和偏好调查结果
Adv Ther. 2017 Jun;34(6):1398-1410. doi: 10.1007/s12325-017-0545-4. Epub 2017 May 8.
9
Nonadherence to Medication in Inflammatory Bowel Disease: Rate and Reasons.炎症性肠病患者的药物治疗不依从性:发生率及原因
Middle East J Dig Dis. 2016 Apr;8(2):116-21. doi: 10.15171/mejdd.2016.16.
10
Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial.比较基于钙卫蛋白的网络辅助治疗算法(IBD-live)与青少年炎症性肠病常规治疗方法的疗效:一项随机对照试验的研究方案。
Trials. 2015 Jun 16;16:271. doi: 10.1186/s13063-015-0787-x.